8-K: Mangoceuticals Sells Additional Series B Preferred Stock in Fourth Closing

Mangoceuticals, Inc. has sold an additional 250 shares of Series B Preferred Stock for $250,000 as part of its ongoing financing agreement.

Summary

• Mangoceuticals, Inc. sold 250 shares of Series B Preferred Stock on September 26, 2024, for $250,000.
• This sale is part of a larger agreement with an institutional investor to sell a total of 2,500 shares of Series B Preferred Stock.
• The current sale is a partial closing of the fourth tranche of the agreement.
• A total of 750 out of 1,000 possible shares for the fourth closing have been sold to date.
• There are 250 Series B Preferred Stock shares remaining available for future sale to the investor.
• Each share of Series B Preferred Stock has a stated value of $1,100, but was sold at a 10% discount.
• The company's stockholders approved the issuance of more than 19.99% of outstanding common stock upon conversion of the Series B Preferred Stock and warrants.
• The sale was exempt from registration under the Securities Act of 1933.
• If converted, the 250 shares could result in a maximum of 1,833,333 shares of common stock being issued, based on a floor price of $0.15 per share.

Sentiment

Score: 6

Explanation: The document indicates a continued capital raise, which is positive for funding but could lead to dilution. The discount on the preferred stock is a slight negative.

Positives

• The company successfully raised $250,000 through the sale of Series B Preferred Stock.
• The company has an ongoing agreement with an institutional investor for further potential capital raises.
• The sale was completed under an existing agreement, indicating a continued relationship with the investor.

Negatives

• The Series B Preferred Stock was sold at a 10% discount to its stated value.
• The potential conversion of the preferred stock could significantly dilute existing common stock holders.

Risks

• The potential conversion of the Series B Preferred Stock could lead to significant dilution of existing common stock.
• The company is reliant on this investor for further capital raises.
• The discount on the sale of the preferred stock may indicate a need for capital.

Future Outlook

The company has 250 remaining shares of Series B Preferred Stock available for future sale to the Purchaser under the existing agreement.

Management Comments

• The company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Industry Context

This type of financing is common for emerging growth companies seeking capital, particularly in the biotech or pharmaceutical sectors. The use of convertible preferred stock allows for flexibility in financing while potentially diluting existing shareholders.

Comparison to Industry Standards

• Many small-cap biotech companies use convertible preferred stock as a financing mechanism, similar to companies like Aeterna Zentaris Inc. and Cassava Sciences, Inc.
• The 10% discount on the stated value of the preferred stock is not uncommon in private placements, but it is important to consider the potential dilution to common shareholders.
• The potential conversion of preferred stock to common stock is a standard practice, but the specific terms and conversion ratios can vary significantly between companies.

Stakeholder Impact

• Shareholders may experience dilution if the Series B Preferred Stock is converted to common stock.
• The company's ability to fund operations is improved by the capital raise.
• The institutional investor has increased its stake in the company.

Next Steps

• The company may sell the remaining 250 shares of Series B Preferred Stock to the Purchaser.
• The company may need to manage the potential dilution of common stock if the preferred stock is converted.

Key Dates

Keywords

Series B Preferred Stock, Securities Purchase Agreement, Convertible Preferred Stock, Capital Raise, Equity Securities, Institutional Investor, Unregistered Sales, Mangoceuticals